Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05896527 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
A Phase 2 study of Plaque Psoriasis, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 229
- Enrollment target
- 20
- Study locations
NCT05896527: Completed Phase 2 study of Plaque Psoriasis, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
NCT05896527 is a Phase 2 study of Plaque Psoriasis that has completed, run by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. The registered enrollment target is 229 participants, below the 411-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05896527, a Phase 2 study of Plaque Psoriasis, has completed, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 229 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a 12-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of DC-806 in participants with moderate to severe plaque psoriasis. This study evaluated the efficacy, safety, tolerability, and pharmacokinetics (PK) of multiple oral doses of DC-806 in participants with moderate to severe plaque psoriasis.
Primary Outcome
Participants achieving a PASI-75 without the use of other background antipsoriasis therapy were considered responders. The PASI quantifies the severity of a psoriasis based on lesion severity and the percent of body surface area (BSA) affected. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no invol
Conditions Studied
Interventions
- OTHER Placebo
- DRUG DC-806
Study Locations (20)
Florida
- Driven Research LLC - Coral Gables
- Kirsch Dermatology - Probity - PPDS - Naples
- GCP Global Clinical Professionals, LLC - St. Petersburg
- ForCare Clinical Research - CenExel FCR - PPDS - Tampa
Ontario
- CCA Medical Research - Probity - PPDS - Ajax
- SimcoDerm Medical and Surgical Dermatology Centre - Probity - PPDS - Barrie
- Dermatrials Research - Hamilton
- Lynderm Research Inc. - Probity - PPDS - Markham
California
- First OC Dermatology - Fountain Valley
- Clinical Science Institute - Santa Monica
Indiana
- The Indiana Clinical Trials Center, PC - Plainfield
Kentucky
- Dermatology Specialists Research - 501 S 2nd St - Louisville
New York
- DICE Therapeutics Study Site - New York
Ohio
- Dermatologists of Southwest Ohio - Probity - PPDS - Mason
Pennsylvania
- Paddington Testing Company Inc - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2023-05-02 |
| Est. Completion | 2024-03-25 |
| Phase | Phase 2 |
What the finished NCT05896527 record still lists
NCT05896527 is an interventional study that assigns participants to a tested intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, below the 411-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05896527 names 20 study sites across 13 states, led by Florida, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT05896527 about?
NCT05896527 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis". This was a 12-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of DC-806 in participants with moderate to severe plaque psoriasis. This study evaluated the efficacy, safety, tolerability, and pharmacokin...
What is the current status of trial NCT05896527?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 229 participants. The study started on 2023-05-02. Estimated completion is 2024-03-25.
What conditions does trial NCT05896527 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT05896527?
The interventions under investigation include: Placebo (OTHER), DC-806 (DRUG).
Who is sponsoring clinical trial NCT05896527?
This trial is sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05896527 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Kentucky, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05896527's enrollment target sits among peer trials
229 17th of 45 higher than 29 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
RECRUITING · Phase 2
-
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
RECRUITING · Phase 2
-
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI